Actualités Oncolytics Biotech Inc - ONC | Actions Toronto Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target ...

CALGARY, Alberta and SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY...

Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC

CALGARY, Alberta and SAN DIEGO, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY...

Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference

CALGARY, Alberta and SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC...

Oncolytics Biotech® Provides Corporate and Clinical Update

- Webcast and conference call for investors and analystson Thursday, September 20 at 8:30 a.m. EDT...

Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) wi...

CALGARY, Alberta and SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC...

Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep

CALGARY, Alberta and SAN DIEGO, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:...

Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Compan...

CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY...

Oncolytics Biotech® Reports 2018 Second Quarter Results

CALGARY, Alberta and SAN DIEGO, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY...

Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference

CALGARY, Alberta and SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC...

Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares

CALGARY, Alberta and SAN DIEGO, June 05, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC...

Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to...

CALGARY, Alberta and SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oncolytics Biotech Inc (ONC)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

ONC Actualités

Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target ...

Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC

Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Oncolytics Biotech® Provides Corporate and Clinical Update

Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) wi...

Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep

Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Compan...

Oncolytics Biotech® Reports 2018 Second Quarter Results

Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference

Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares

Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to...

Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares

Oncolytics Biotech® Announces Listing on Nasdaq Capital Market

Oncolytics Biotech® Announces Public Offering of Common Shares

Oncolytics Biotech® Announces New OTCQX Ticker Symbol

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oncolytics Biotech Inc (ONC) Actualités

Oncolytics Biotech Inc (ONC)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

ONC Actualités

Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target ...

Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC

Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Oncolytics Biotech® Provides Corporate and Clinical Update

Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) wi...

Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep

Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Compan...

Oncolytics Biotech® Reports 2018 Second Quarter Results

Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference

Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares

Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to...

Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares

Oncolytics Biotech® Announces Listing on Nasdaq Capital Market

Oncolytics Biotech® Announces Public Offering of Common Shares

Oncolytics Biotech® Announces New OTCQX Ticker Symbol

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application